What is the impact to the treatment landscape from the early benefits seen in the EMPEROR trials?
Featuring
Professor Andrew Coats | Australia
Related content
Document ID: PC-ASK-100093
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
The heart failure patient through a holistic lens (Full)
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
The heart failure patient through a holistic lens (Summary)
Subodh Verma (Canada) | Soo Yong Lee (Korea)
SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 1)
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
Clinical relationship between the heart and the kidneys
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)